96 related articles for article (PubMed ID: 15766819)
1. Did they lower stress in the trial? Or was it just wasted energy?
Sanders SP
J Am Coll Cardiol; 2005 Mar; 45(6):858-9. PubMed ID: 15766819
[No Abstract] [Full Text] [Related]
2. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.
Duboc D; Meune C; Lerebours G; Devaux JY; Vaksmann G; Bécane HM
J Am Coll Cardiol; 2005 Mar; 45(6):855-7. PubMed ID: 15766818
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
Ramaciotti C; Heistein LC; Coursey M; Lemler MS; Eapen RS; Iannaccone ST; Scott WA
Am J Cardiol; 2006 Sep; 98(6):825-7. PubMed ID: 16950195
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life.
Giglio V
Am J Cardiol; 2007 Jan; 99(1):147-8. PubMed ID: 17196482
[No Abstract] [Full Text] [Related]
5. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up.
Duboc D; Meune C; Pierre B; Wahbi K; Eymard B; Toutain A; Berard C; Vaksmann G; Weber S; Bécane HM
Am Heart J; 2007 Sep; 154(3):596-602. PubMed ID: 17719312
[TBL] [Abstract][Full Text] [Related]
6. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
[TBL] [Abstract][Full Text] [Related]
7. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
8. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
9. Does ACE inhibitor therapy delay onset and progression of cardiac dysfunction in duchenne muscular dystrophy?
Hirano M
Curr Neurol Neurosci Rep; 2006 Jan; 6(1):35-6. PubMed ID: 16469269
[No Abstract] [Full Text] [Related]
10. Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?
Frohlich ED
J Am Coll Cardiol; 2004 Jun; 43(12):2216-8. PubMed ID: 15193682
[No Abstract] [Full Text] [Related]
11. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
[TBL] [Abstract][Full Text] [Related]
12. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
13. Small benefits in trastuzumab-related cardiotoxicity.
Das M
Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
[No Abstract] [Full Text] [Related]
14. I have been diagnosed with a poor ejection fraction from my left ventricle. What does that mean, and what medications would be most beneficial?
Health News; 2006 Feb; 12(2):16. PubMed ID: 16453941
[No Abstract] [Full Text] [Related]
15. Improving endothelial function and reducing remodeling post-MI are key to perindopril benefits in coronary artery disease.
Cardiovasc J S Afr; 2006; 17(4):203-4. PubMed ID: 17001425
[No Abstract] [Full Text] [Related]
16. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.
Finsterer J; Stöllberger C
Neuromuscul Disord; 2009 Jan; 19(1):74; author reply 75. PubMed ID: 19070488
[No Abstract] [Full Text] [Related]
17. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy.
Silversides CK; Webb GD; Harris VA; Biggar DW
Am J Cardiol; 2003 Mar; 91(6):769-72. PubMed ID: 12633823
[No Abstract] [Full Text] [Related]
18. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
19. Effects of cardiac medications on ventricular function in patients with Duchenne muscular dystrophy-related cardiomyopathy.
Murphy AP; Johnson A; Straub V; Heads-Baister A; Lord S; Bourke JP
Muscle Nerve; 2021 Aug; 64(2):163-171. PubMed ID: 34050938
[TBL] [Abstract][Full Text] [Related]
20. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
